Get the Stockscreener App
10.61
1.58%
-0.17
After Hours:
10.61
Arvinas Inc stock is traded at $10.61, with a volume of 721.01K.
It is down -1.58% in the last 24 hours and down -2.21% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$10.78
Open:
$10.85
24h Volume:
721.01K
Relative Volume:
0.85
Market Cap:
$684.53M
Revenue:
$262.60M
Net Income/Loss:
$-80.80M
P/E Ratio:
-8.7246
EPS:
-1.2161
Net Cash Flow:
$-275.70M
1W Performance:
+3.82%
1M Performance:
-2.21%
6M Performance:
+10.87%
1Y Performance:
+39.06%
1-Day Range:
$10.28
$11.00
1-Week Range:
$9.73
$11.40
52-Week Range:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.61 | 695.50M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
What Arvinas says on May 12: Q1 results and corporate update - Stock Titan
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - Caledonian Record
ARVN Maintained by Citigroup -- Price Target Raised to $24 - GuruFocus
Arvinas/Pfizer To Announce Veppanu Commercialization Partner In Weeks - Citeline News & Insights
Arvinas (NASDAQ:ARVN) Shares Gap DownShould You Sell? - MarketBeat
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations - BioSpace
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data - BioSpace
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN - MarketBeat
Arvinas’ Veppanu, First Breast Cancer Drug of Its Kind Approved by FDA, Seeks Commercialization Partner - geneonline.com
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones - Yahoo Finance
FDA approves Pfizer-Arvinas breast cancer pill Veppanu for advanced cases - Investing.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
FDA Approves Pfizer and Arvinas Breast Cancer Drug - Intellectia AI
US FDA approves Pfizer, Arvinas' breast cancer drug - Reuters
Truist Financial Maintains Arvinas(ARVN.US) With Hold Rating, Announces Target Price $10 - Moomoo
FDA Approves Vepdegestrant for Advanced Breast Cancer Treatment - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Up 9.9%What's Next? - MarketBeat
BTIG reiterates Arvinas stock rating on breast cancer drug approval By Investing.com - Investing.com South Africa
BTIG reiterates Arvinas stock rating on breast cancer drug approval - Investing.com
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA - BioPharma Dive
FDA approves first PROTAC drug for ESR1-mutated breast cancer - Stock Titan
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era - Intellectia AI
Arvinas (ARVN) Secures Early Approval for Vepdeg in Breast Cance - GuruFocus
Arvinas shares gain as FDA approves breast cancer drug Veppanu - Investing.com
US FDA approves Pfizer, Arvinas’ breast cancer drug - WKZO
Arvinas Gains First FDA Approval for Breast Cancer Drug - TipRanks
Pfizer, Arvinas breast cancer drug approved (update) (PFE:NYSE) - Seeking Alpha
Arvinas shares gain as FDA approves breast cancer drug Veppanu By Investing.com - Investing.com Canada
FDA approves Arvinas’ vepdegestrant for breast cancer treatment By Investing.com - Investing.com Canada
Arvinas announces FDA approval of Veppanu for treatment of ESR1m, ER+/HER2- advanced breast cancer - marketscreener.com
FDA clears Arvinas (NASDAQ: ARVN) VEPPANU for advanced breast cancer - Stock Titan
FDA approves Arvinas’ vepdegestrant for breast cancer treatment - Investing.com UK
Arvinas and Pfizer Announce FDA Approval of VEPPANU™ as First-Ever PROTAC for Advanced Breast Cancer Treatment - Quiver Quantitative
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) - GlobeNewswire
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - MSN
(ARVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
[ARS] ARVINAS, INC. SEC Filing - Stock Titan
Arvinas (NASDAQ: ARVN) details 2026 virtual meeting, director and pay votes - Stock Titan
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Vanguard Portfolio Management owns 3.92M Arvinas shares (ARVN) - Stock Titan
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
Arvinas announces $100M share repurchase program - MSN
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas earns relative strength rating upgrade; hits key benchmark - MSN
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):